Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Institute for Science and International Security Stories

2014-04-01 08:27:58

CARLSBAD, Calif., April 1, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 13(th) Annual Needham Healthcare Conference on Tuesday, April 8 , 2014 at 12:50 p.m. ET in New York, NY. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website,...

2014-03-06 08:30:03

CARLSBAD, Calif., March 6, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Thursday, March 13, 2014 at 9:00 a.m. ET in Miami, FL. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website,...

2014-03-03 08:30:46

CARLSBAD, Calif., March 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of an open-label extension study of ISIS-TTR(Rx), which is being offered to those patients with familial amyloid polyneuropathy (FAP) who have completed dosing in the Phase 2/3 study of ISIS-TTR(Rx). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO ISIS-TTR(Rx) is...

2014-02-28 08:25:30

- Outperforms 2013 Projections for Pro Forma Net Operating Loss and Year-end Cash CARLSBAD, Calif., Feb. 28, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2013 financial results and reviewed the highlights of the year. Isis ended the year in a strong financial position and outperformed both its pro forma net operating loss (NOL) guidance and its cash guidance for the year. For the year ended December 31, 2013, Isis had an NOL of $40.2 million compared to...

2014-02-06 08:27:39

CARLSBAD, Calif., Feb. 6, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2014 Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 1:50 p.m. ET in New York, NY. (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's...

2014-02-03 16:24:54

CARLSBAD, Calif., Feb. 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that Joseph Loscalzo, M.D., Ph.D., has joined the company's Board of Directors. Dr. Loscalzo is head of the department of medicine and physician-in-chief at Brigham & Women's Hospital, Harvard Medical School. Dr. Loscalzo is recognized as a leading cardiologist focused on identifying the role of endothelial cells and platelets in atherosclerosis and thrombosis. (Logo:...

2014-01-13 16:26:10

CARLSBAD, Calif., Jan. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will receive $7.5 million from Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from the recently announced alliance between Genzyme and Alnylam. In addition, Isis has the potential to receive royalties on products and a portion of future milestone payments. This transaction underscores the value of Isis' innovation and the leadership role Isis has played in the field of...

2013-12-23 08:24:37

NEW YORK, December 23, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Laboratory Corp. of America Holdings (NYSE: LH), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), Mindray Medical International Limited (NYSE: MR), Clovis Oncology, Inc. (NASDAQ: CLVS), and Sangamo Biosciences Inc. (NASDAQ: SGMO). Today's readers may access these reports free of charge -...

2013-11-26 08:26:56

CARLSBAD, Calif., Nov. 26, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 study for ISIS-GSK3(Rx) and earned a $3 million milestone payment from GlaxoSmithKline (GSK). ISIS-GSK3(Rx )is designed to inhibit the production of an undisclosed target to treat a common viral infection. Isis will develop ISIS-GSK3(Rx) to Phase 2 proof-of-concept, after which GSK has an exclusive option to in-license the program and further...

2013-11-25 08:26:31

CARLSBAD, Calif., Nov. 25, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2013 Deutsche Bank BioFEST on Monday, December 2, 2013 at 8:25 a.m. ET in Boston, MA. (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's website,...